Fig 2: Depletion of HMMR inhibits growth and migration of LUAD cells in vivro. (A) IHC analysis of HMMR in LUAD. (B) The expression of HMMR in LUAD cell lines by qRT-PCR. (C, D) Establishment of HMMR knockdown in A549 and H1299 cell lines and verified by qRT-PCR and Western blot. (E) The growth curve assay was employed detect the proliferation of LUAD cells. (F) The colony formation assay was employed detect the proliferation of LUAD cells. (G) The transwell assay was employed detect the migration of LUAD cells, (H) The wound healing assay was employed detect the migration of LUAD cells. P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***), P < 0.0001 (***) was considered significantly.

Fig 3: Predicted and analysis the upstream LncRNAs of let-7b-5p in LUAD. (A) The target sites between the TMPO-AS1 and hsa-let-7b-5p were predicted by starbase. (B) The correlation between hsa-let-7b-5p expression and TMPO-AS1 analysis by starbase. (C) The correlation between the HMMR expression and TMPO-AS1 analysis by starbase. (D) The expression of TMPO-AS1 in LUAD analysis by starbase. (E, F) The prognosis of TMPO-AS1 in LUAD analysis by kmplot. (G) The ROC curve of TMPO-AS1 in LUAD. (H) The subcellular localization of TMPO-AS1 analysis by the lncLocator tools. (I) The coding potential of TMPO-AS1 analysis by the coding potential calculator. (J) The HMMR and hsa-let-7b-5p expression after depletion of TMPO-AS1 in LUAD cells analysis by qRT-PCR assay. (K) The DNA methylation of TMPO-AS1 in LUAD. (L) The correlation between DNA methylation and expression of TMPO-AS1 in LUAD. (M) The expression of TMPO-AS1 in LUAD cells after treat with 5Aza examined by qRT-PCR assay. P >0.05 (ns), P < 0.001 (***), was considered significantly.

Fig 4: Predicted and analysis the upstream miRNAs of HMMR in LUAD. (A) The correlation between the HMMR expression and miRNA-18a-5p, miR-33a-5p and miR-369-3p analysis by starBase. (B) The target sites between HMMR and hsa-let-7b-5p were predicted by starBase. (C) The correlation between the HMMR expression and hsa-let-7b-5p analysis by starbase. (D) The expression of hsa-let-7b-5p in LUAD analysis by TCGA. (E–G) The correlation between hsa-let-7b-5p expression and clinical features in LUAD. (H) The prognosis of hsa-let-7b-5p in LUAD analysis by kmplot. (I) The ROC curve of hsa-let-7b-5p in LUAD. (J) The expression of hsa-let-7b-5p in LUAD cells analysis by employed qRT-PCR assay. (K) The expression of HMMR after overexpression of hsa-let-7b-5p in LUAD cells analysis by qRT-PCR assay. (L) The expression of HMMR after overexpression of hsa-let-7b-5p in LUAD Cells analysis by western blot assay. NC, Negative control. P > 0.05 (ns), ***P < 0.001, was considered significantly.

Fig 5: HMMR was highly expressed in pan-cancer. (A) The expression of HMMR in pan-cancers examined by TIMER tools. (B) The expression of HMMR in pan-cancers examined by GEPIA tools. (C) The expression of HMMR in pan-cancers cells lines examined by CCLE database. *P < 0.05; ***P < 0.001.